The report is a complex analysis of OTC drug and dietary supplement markets in eight countries in the region:
- the Czech Republic
It analyses the market value in particular countries, as well as in the whole
CEE region and pays particular attention to such information as OTC drug
market value, dietary supplement market value, share of OTC in the total
market, best-selling OTC products, leading OTC manufacturers, and
non-pharmacy and online sales of OTC products.
The publication also contains forecasts up to 2013 for OTC drug/product
markets in particular countries as well as for the whole region, prepared
by a team of pharmaceutical market analysts and PMR's economy experts. The
report is complemented with the analysis of distribution segments in
particular countries. It is a unique publication which presents all the
important information regarding the OTC product market in the CEE region on
more than 300 pages.
Key topics covered:
- best selling OTC drugs in individual countries
- best selling dietary supplements in individual countries
- leading OTC drug manufacturers in individual countries
- profiles of leading regional OTC manufacturers
- leading dietary supplement manufacturers in individual countries
- OTC drug market value 2007-2013 in individual countries
- dietary supplements market value in individual countries
- share of OTC in total pharmacy sales in individual countries
- sales structure of OTC products in pharmacy sales in individual countries
- regulations regarding non-pharmacy sales of OTC products in individual
- regulations regarding online sales of OTC products in individual countries
- largest advertisers in the OTC segment in individual countries
- largest pharmacy chains in individual countries
- largest wholesalers in individual countries
- main events and trends in individual countries
- comparative analysis of OTC market value, share of OTC as a proportion of
the entire market and share of dietary supplements as a proportion of the
- consumer behaviours regarding OTC product intake in individual countries
- epidemiological trends.
When will the report prove useful?
- when starting a business on the OTCmarket in CEE
- when developing OTC products sales in CEE
- when analysing competitors
- when analysing the market saturation
- when developing OTC products portfolio in a particular CEE country.
- all information regarding the OTC products segment in CEE in one place
- comparative analysis of OTC product markets in 8 countries
- the report provides broad range of historical data as it is its third
- development forecasts for 2011-2013.
Find answers for the following questions:
- In which country is the OTC market the largest?
- In which country has the OTC market the highest growth potential?
- Which CEE country has the " friendliest" environment for OTC products?
- In which country is the OTC market profoundly saturated?
- What are the strategies OTC manufacturers introduce into the market in CEE?
This report is adressed to:
- the senior management of OTC companies active in the region
- pharmaceutical wholesalers and distributors
- non-pharmacy and on-line drug distributors
- research and analytical institutions
- embassies and other government institutions.
Companies mentioned in this report:
Actavis, Akvion, Bayer, Beres, Berlin-Chemie/Menarini, Boehringer Ingelheim,
Bristol-Myers Squibb, Diod, Evalar, Farmak, Gedeon Richter, GlaxoSmithKline,
Johnson & Johnson, Maspex, Novartis, NP Pharma, Ozone Laboratories, Pfizer,
Pharmstandard, Reckitt Benckiser, RIA Panda, Sandoz, Sanofi, Sopharma, Stada,
Teva, US Pharmacia, Walmark.
Extract from this report
- According to our forecasts, in the next three years the most attractive of
the analysed markets in the region, taking into account forecasted market
growth, will be Bulgaria.
- According to our forecasts, in 2011 the OTC market in Central and Eastern
Europe will grow by close to 10% in real terms. In 2012 it will see a positive
growth rate of more than 9%, whereas in 2013 it will expand by around 8%.
Market commentary by expert
According to our estimates, in 2010 the OTC market in the CEE region was worth
some € 10.7bn, which represented an increase of approx. 13% y-o-y in euro
terms. A half was generated by Russia. In 2010, Poland was the second largest
OTC market in the region, with a share in total sales of around 23%. Ukraine
accounted for around 7% of all OTC business on the CEE market. According to
our forecasts, between 2011 and 2013 the market will expand by around 9% on
average per annum. Bulgaria and Ukraine will be the fastest developing markets
in the region in the analysed period. Agnieszka Skonieczna,
Pharmaceutical Market Analyst